Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Head and neck squamous cell carcinoma, drawn from the whole corpus: 210 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
6 medicines on record are linked to one of the types below rather than to Head and neck squamous cell carcinoma itself. Grouped by the type that holds them; each list opens that type's own page.
Functional toxicity of chemoradiation.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Few targets beyond EGFR/PD-1.
HPV-negative, tobacco-related disease has 5-year survival around 50% and has seen little improvement in curative outcomes beyond KEYNOTE-689.
De-escalation for HPV-positive disease has failed in every randomised trial; the field still lacks a validated way to identify who can receive less.
Only two drug targets (EGFR and PD-1) have approved agents; PIK3CA, NOTCH, and CDKN2A alterations remain undrugged.
Immunotherapy concurrent with chemoradiation has failed three times; the mechanism is not fully understood.
Curative treatment causes permanent swallowing, speech, dental, and thyroid damage; survivorship care is under-resourced.
Nasopharyngeal carcinoma outside East Asia is rare and under-studied; EBV-directed cell therapies remain experimental.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Second primary cancers and field cancerisation in smokers are not addressed by any approved chemoprevention.
Global burden falls on South Asia (oral cavity cancer from smokeless tobacco and areca nut), where access to IMRT and immunotherapy is limited.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 53 changes by month →When this page itself was last checked or edited.
Median OS 10 vs 5 months, HR 0.
Median EFS 59.
Three-year disease-free survival 63.
HN005: de-escalated arms had worse PFS; control 2-year PFS 98%.
Severe oral mucositis incidence 54% vs 64% (relative risk 0.